Implanet SA (DE:IM11)

FRANKFURT:IM11

IM11

Implanet SA

RESEARCH TOOLSreports

Implanet SA (IM11) Price & Analysis

― Followers

IM11 Stock Chart & Stats

€0.28

>-€0.01(-1.68%)

At close: Jan 08 4:00 PM EST

€0.28

>-€0.01(-1.68%)

Day’s Range― - ―

52-Week Range€0.08 - €0.42

Previous CloseN/A

Volume0.00

Average Volume (3M)4.40K

Market Cap

€31.42M

Enterprise Value€34.34M

Total Cash (Recent Filing)€3.01M

Total Debt (Recent Filing)€5.92M

Price to Earnings (P/E)―

Beta0.32

Next Earnings

Sep 22, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding143,818,970

10 Day Avg. Volume3,845

30 Day Avg. Volume4,401

Financial Highlights & Ratios

PEG Ratio0.35

Price to Book (P/B)70.59

Price to Sales (P/S)2.29

P/FCF Ratio-13.27

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Sustained Revenue GrowthTop-line has shown a multi-year rebound, signaling stronger market adoption of Implanet’s implant systems. Durable revenue growth over several years suggests expanding procedure volume or penetration, improving the company’s ability to scale fixed costs and fund product development long term.

Improving Gross MarginsA meaningful margin expansion implies better product mix, pricing power or manufacturing/scale gains. Higher gross margins create structural room to absorb commercial and R&D spend and are a prerequisite for sustainable operating profitability if the company controls operating expenses.

Per‑procedure, Recurring Revenue ModelThe implant business earns recurring revenues tied to procedures and repeat consumable purchases. An installed base of reusable instruments plus disposables creates predictable demand streams and lifecycle revenues that support durable cash generation as surgeon adoption increases.

Bears Say

Negative Cash GenerationConsistent negative operating and free cash flow forces reliance on external financing for operations and growth. Until OCF turns sustainably positive, the company faces funding risk that can constrain commercialization, delay R&D or dilute shareholders if new capital is required.

High Leverage And Thin EquityA capital structure with elevated debt and minimal equity offers little cushion for ongoing losses. High leverage reduces financial flexibility, raises refinancing risk, and could limit investment in sales or R&D if lenders or markets tighten, impairing long-term strategic options.

Persistent Loss-MakingDespite revenue and margin gains, deep negative net margins indicate the business has not yet reached structural profitability. Continued losses may necessitate sustained capital raises and indicate that fixed and SG&A costs still outpace core profitability during scale-up.

IM11 FAQ

What was Implanet SA’s price range in the past 12 months?

Implanet SA lowest stock price was €0.07 and its highest was €0.42 in the past 12 months.

What is Implanet SA’s market cap?

Implanet SA’s market cap is €31.42M.

When is Implanet SA’s upcoming earnings report date?

Implanet SA’s upcoming earnings report date is Sep 22, 2026 which is in 166 days.

How were Implanet SA’s earnings last quarter?

Implanet SA released its earnings results on Feb 24, 2026. The company reported -€0.014 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.014.

Is Implanet SA overvalued?

According to Wall Street analysts Implanet SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Implanet SA pay dividends?

Implanet SA does not currently pay dividends.

What is Implanet SA’s EPS estimate?

Implanet SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Implanet SA have?

Implanet SA has 143,818,970 shares outstanding.

What happened to Implanet SA’s price movement after its last earnings report?

Implanet SA reported an EPS of -€0.014 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.723%.

Which hedge fund is a major shareholder of Implanet SA?

Currently, no hedge funds are holding shares in DE:IM11

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Implanet SA

Implanet S.A., together with its subsidiaries, researches and develops, manufactures, and sells spinal and orthopedic implants. The company offers spinal and knee products. Its products include Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Jazz Frame, and ISS-Jazz Screw systems for posterior fixation. The company also provides knee prostheses under the Madison name. Implanet S.A. has a strategic partnership with Shanghai Sanyou Medical Co, Ltd. The company was founded in 2006 and is based in Martillac, France.